Evidence map›Paper›PMID 27506584›Full record

ArticleDiabetologia2016

Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes.

Sarah J Richardson, Teresa Rodriguez-Calvo, Ivan C Gerling, Clayton E Mathews, John S Kaddis, Mark A Russell, Marie Zeissler, Pia Leete, Lars Krogvold, Knut Dahl-Jørgensen and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 200 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
200citing papers in PubMed, 2 pooled it
23.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

200 citing papers in PubMed, 2 syntheses or guidelines pooled it, 291 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. ProtectiveiScience · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. New and emerging therapies in type 1 diabetes mellitus.The Journal of clinical investigation · 2026
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

140 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 3 countries.

Sarah J RichardsonIslet Biology Exeter (IBEx), Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, RILD Building (Level 4), Barrack Road, Exeter, EX2 5DW, UK. s.richardson@exeter.ac.uk.
Teresa Rodriguez-CalvoLa Jolla Institute for Allergy and Immunology, San Diego, CA, USA.
Ivan C GerlingDepartment of Medicine, University of Tennessee, Memphis, TN, USA.
Clayton E MathewsDepartment of Pathology, University of Florida, Gainesville, FL, USA.
John S KaddisDepartment of Information Sciences, City of Hope, Duarte, CA, USA.
Mark A RussellIslet Biology Exeter (IBEx), Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, RILD Building (Level 4), Barrack Road, Exeter, EX2 5DW, UK.
Marie ZeisslerIslet Biology Exeter (IBEx), Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, RILD Building (Level 4), Barrack Road, Exeter, EX2 5DW, UK.
Pia LeeteIslet Biology Exeter (IBEx), Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, RILD Building (Level 4), Barrack Road, Exeter, EX2 5DW, UK.
Lars KrogvoldPaediatric Department, Oslo University Hospital, Oslo, Norway.
Knut Dahl-JørgensenPaediatric Department, Oslo University Hospital, Oslo, Norway.
Matthias von HerrathLa Jolla Institute for Allergy and Immunology, San Diego, CA, USA.
Alberto PuglieseDiabetes Research Institute, Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Miami Miller School of Medicine, Miami, FL, USA.
Mark A AtkinsonDepartment of Pathology, University of Florida, Gainesville, FL, USA.
Noel G MorganIslet Biology Exeter (IBEx), Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, RILD Building (Level 4), Barrack Road, Exeter, EX2 5DW, UK. n.g.morgan@exeter.ac.uk.
University of Exeter · GBLa Jolla Institute for Immunology · USUniversity of Florida · USUniversity of Oslo · NOCity of Hope · USUniversity of Miami · USUniversity of Tennessee Health Science Center · US

Funding

Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 DiabetesR01AI092453 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Estefania Quesada Masachs · 2011 to 2026
$5.7M
Genetic Regulation of Human Beta Cell DestructionUC4DK104194 · NIDDK · UNIVERSITY OF FLORIDA · PI MATHEWS, CLAYTON E · 2014 to 2014
$3.1M
mt-Nd2 and Resistance to Autoimmune DiabetesR01DK074656 · NIDDK · UNIVERSITY OF FLORIDA · PI MATHEWS, CLAYTON E · 2006 to 2015
$2.8M
Defining Islet Heterogeneity Using Single Islet TranscriptomicsUC4DK104155 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI CAMPBELL-THOMPSON, MARTHA, GERLING, IVAN C · 2014 to 2014
$1.6M
NIAID NIH HHS R01 AI092453NIDDK NIH HHS R01 DK074656NIDDK NIH HHS UC4 DK104155NIDDK NIH HHS UC4 DK104194
6 · The paper itself

Abstract

aims/hypothesisHuman pancreatic beta cells may be complicit in their own demise in type 1 diabetes, but how this occurs remains unclear. One potentially contributing factor is hyperexpression of HLA class I antigens. This was first described approximately 30 years ago, but has never been fully characterised and was recently challenged as artefactual. Therefore, we investigated HLA class I expression at the protein and RNA levels in pancreases from three cohorts of patients with type 1 diabetes. The principal aims were to consider whether HLA class I hyperexpression is artefactual and, if not, to determine the factors driving it.

methodsPancreas samples from type 1 diabetes patients with residual insulin-containing islets (n = 26) from the Network for Pancreatic Organ donors with Diabetes (nPOD), Diabetes Virus Detection study (DiViD) and UK recent-onset type 1 diabetes collections were immunostained for HLA class I isoforms, signal transducer and activator of transcription 1 (STAT1), NLR family CARD domain containing 5 (NLRC5) and islet hormones. RNA was extracted from islets isolated by laser-capture microdissection from nPOD and DiViD samples and analysed using gene-expression arrays.

resultsHyperexpression of HLA class I was observed in the insulin-containing islets of type 1 diabetes patients from all three tissue collections, and was confirmed at both the RNA and protein levels. The expression of β2-microglobulin (a second component required for the generation of functional HLA class I complexes) was also elevated. Both 'classical' HLA class I isoforms (i.e. HLA-ABC) as well as a 'non-classical' HLA molecule, HLA-F, were hyperexpressed in insulin-containing islets. This hyperexpression did not correlate with detectable upregulation of the transcriptional regulator NLRC5. However, it was strongly associated with increased STAT1 expression in all three cohorts. Islet hyperexpression of HLA class I molecules occurred in the insulin-containing islets of patients with recent-onset type 1 diabetes and was also detectable in many patients with disease duration of up to 11 years, declining thereafter. CONCLUSIONS/

interpretationIslet cell HLA class I hyperexpression is not an artefact, but is a hallmark in the immunopathogenesis of type 1 diabetes. The response is closely associated with elevated expression of STAT1 and, together, these occur uniquely in patients with type 1 diabetes, thereby contributing to their selective susceptibility to autoimmune-mediated destruction.

Indexed as

Diabetes Mellitus, Type 1FemaleFluorescent Antibody TechniqueHistocompatibility Antigens Class IHumansImmunohistochemistryInsulinIn Vitro TechniquesIslets of LangerhansMalePancreasSTAT1 Transcription FactorHistocompatibility Antigens Class IInsulinSTAT1 Transcription FactorDiViDHLA class IHLA-FIslet cellnPODPancreasSTAT1Type 1 diabetes

Identifiers

PMID27506584
PMCPMC5042874
OpenAlexW2513957711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.